Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.55 Million USD | -71.23% |
| 2022 | 96.54 Million USD | -43.54% |
| 2021 | 170.99 Million USD | 65.05% |
| 2020 | 103.6 Million USD | 96.43% |
| 2019 | 52.74 Million USD | -32.07% |
| 2018 | 77.64 Million USD | 672.96% |
| 2017 | 10.04 Million USD | -16.59% |
| 2016 | 12.04 Million USD | -71.36% |
| 2015 | 42.04 Million USD | 338.42% |
| 2014 | 9.59 Million USD | -33.5% |
| 2013 | 14.42 Million USD | 146.92% |
| 2012 | 5.84 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.7 Million USD | -20.76% |
| 2024 Q2 | 4.73 Million USD | -2.72% |
| 2023 Q2 | 7.5 Million USD | -6.38% |
| 2023 Q1 | 8.01 Million USD | -32.38% |
| 2023 FY | 27.77 Million USD | -71.23% |
| 2023 Q4 | 7.19 Million USD | 6.24% |
| 2023 Q3 | 6.77 Million USD | -9.68% |
| 2022 Q1 | 32.11 Million USD | -18.15% |
| 2022 FY | 96.54 Million USD | -43.54% |
| 2022 Q4 | 11.84 Million USD | -49.4% |
| 2022 Q3 | 23.41 Million USD | -19.72% |
| 2022 Q2 | 29.16 Million USD | -9.17% |
| 2021 Q2 | 42.16 Million USD | -7.28% |
| 2021 Q3 | 44.12 Million USD | 4.66% |
| 2021 FY | 170.99 Million USD | 65.05% |
| 2021 Q4 | 39.23 Million USD | -11.09% |
| 2021 Q1 | 45.47 Million USD | 26.77% |
| 2020 Q1 | 19.24 Million USD | 49.5% |
| 2020 Q2 | 22.37 Million USD | 16.25% |
| 2020 Q4 | 35.86 Million USD | 37.34% |
| 2020 Q3 | 26.11 Million USD | 16.74% |
| 2020 FY | 103.6 Million USD | 96.43% |
| 2019 Q1 | 13.63 Million USD | -9.0% |
| 2019 Q4 | 12.87 Million USD | -9.97% |
| 2019 Q3 | 14.29 Million USD | 19.73% |
| 2019 Q2 | 11.94 Million USD | -12.4% |
| 2019 FY | 52.74 Million USD | -32.07% |
| 2018 FY | 77.64 Million USD | 672.96% |
| 2018 Q4 | 14.98 Million USD | -18.73% |
| 2018 Q3 | 18.43 Million USD | -20.69% |
| 2018 Q2 | 23.24 Million USD | 10.75% |
| 2018 Q1 | 20.98 Million USD | 785.13% |
| 2017 Q1 | 3.02 Million USD | 52.72% |
| 2017 FY | 10.04 Million USD | -16.59% |
| 2017 Q4 | 2.37 Million USD | 30.29% |
| 2017 Q3 | 1.81 Million USD | -35.65% |
| 2017 Q2 | 2.82 Million USD | -6.55% |
| 2016 Q2 | 2.51 Million USD | -56.41% |
| 2016 Q4 | 1.98 Million USD | 5.95% |
| 2016 FY | 12.04 Million USD | -71.36% |
| 2016 Q3 | 1.87 Million USD | -25.78% |
| 2016 Q1 | 5.78 Million USD | -37.38% |
| 2015 Q1 | 6.63 Million USD | 103.76% |
| 2015 FY | 42.04 Million USD | 338.42% |
| 2015 Q4 | 9.23 Million USD | -45.63% |
| 2015 Q3 | 16.98 Million USD | 84.58% |
| 2015 Q2 | 9.19 Million USD | 38.58% |
| 2014 Q2 | 1.98 Million USD | -20.21% |
| 2014 Q1 | 2.48 Million USD | -2.08% |
| 2014 FY | 9.59 Million USD | -33.5% |
| 2014 Q4 | 3.25 Million USD | 74.63% |
| 2014 Q3 | 1.86 Million USD | -5.92% |
| 2013 FY | 14.42 Million USD | 146.92% |
| 2013 Q4 | 2.53 Million USD | 0.0% |
| 2012 FY | 5.84 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2112.993% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -486.131% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1225.319% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4350.753% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 20.675% |
| Qrons Inc. | 643.67 Thousand USD | -4491.278% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7486.134% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 48.55% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7012.995% |
| Skye Bioscience, Inc. | 13.54 Million USD | -118.143% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 65.947% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -500.926% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -11191.58% |
| SQZ Biotechnologies Company | 85.61 Million USD | 65.483% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -913.396% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1867.709% |
| Mesoblast Limited | 5.9 Million USD | -400.729% |
| Marizyme, Inc. | 19.23 Million USD | -53.603% |
| Genus plc | 147.7 Million USD | 79.991% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -236.624% |
| Pharming Group N.V. | 225.49 Million USD | 86.894% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1342.521% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2102.908% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -254.395% |
| ContraFect Corporation | 56.88 Million USD | 48.051% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -570.338% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1898.51% |
| IMV Inc. | 37.7 Million USD | 21.629% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -959.112% |
| MultiCell Technologies, Inc. | 567.42 USD | -5208211.304% |
| ONE Bio Corp. | 6.44 Million USD | -358.62% |
| Accustem Sciences Inc. | 3.74 Million USD | -688.833% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 65.614% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5455.472% |
| Q BioMed Inc. | 3.43 Million USD | -759.942% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -19.575% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1024.748% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2872.595% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 70.248% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1579.455% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -339.907% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1485.147% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 118312.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -84.588% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1510.434% |
| GB Sciences, Inc. | 1.42 Million USD | -1980.451% |
| Alpha Cognition Inc. | 9.7 Million USD | -204.494% |
| HST Global, Inc. | 140.9 Thousand USD | -20873.408% |
| CSL Limited | 3.44 Billion USD | 99.143% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2527.144% |
| Halberd Corporation | 74.84 Thousand USD | -39387.186% |
| Enzolytics Inc. | 2.17 Million USD | -1255.949% |
| Agentix Corp. | 1.37 Million USD | -2054.392% |
| Resverlogix Corp. | 12.71 Million USD | -132.481% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -709.514% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.073% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2730.747% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1128.849% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1771.207% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -767.935% |
| AVAX Technologies, Inc. | 7.31 Million USD | -304.267% |
| Zenith Capital Corp. | 8.94 Million USD | -230.46% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.419% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -169540.09% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1103.633% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -17131.166% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1438.493% |
| Kadimastem Ltd | 2.41 Million USD | -1126.209% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1398.605% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -171.952% |
| BioStem Technologies, Inc. | 22.97 Million USD | -28.632% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -16183.99% |
| LadRx Corporation | 3.81 Million USD | -675.305% |
| Cell Source, Inc. | 4.32 Million USD | -583.252% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3100.074% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3100.074% |
| NovAccess Global Inc. | 2.46 Million USD | -1098.049% |
| Affymax, Inc. | 39.38 Million USD | 24.966% |
| Itoco Inc. | 919.14 Thousand USD | -3115.278% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -597.266% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2541.019% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5229.224% |
| CytoDyn Inc. | 18.05 Million USD | -63.656% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -117318.253% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -13328.421% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1981.502% |
| SYBLEU INC | 160.87 Thousand USD | -18270.049% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1527.081% |
| International Stem Cell Corporation | 5.27 Million USD | -460.672% |
| Bioxytran, Inc. | 3.82 Million USD | -673.609% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -56039.584% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -145173.558% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 18.51% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1726.514% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3916.254% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -849.952% |
| Neutra Corp. | 243.82 Thousand USD | -12020.777% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -69.29% |
| PureTech Health plc | 144.59 Million USD | 79.562% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -44.232% |
| IXICO plc | 4.7 Million USD | -527.852% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -235.944% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 74.901% |
| CSL Limited | 3.89 Billion USD | 99.241% |
| Cellectis S.A. | 97.32 Million USD | 69.633% |